Ranbaxy's launches Clarithromycin

Mumbai, July 17 (UNI) Ranbaxy Laboratories today announced that Nihon Pharmaceutical Industry(NPI), a joint venture between the company and Nippon Chemiphar Ltd, has launched Clarithromycin 50mg, 200mg tablets and Terbinafine 125mg tablets.

Informing the BSE, the company said Clarithromycin is an antibiotic and Terbinafine, an anti-fungal with a market size of around US dolalr 400 million and USD 300 million, respectively, in Japan, for the above dosage forms. The products will be sold in Japan under Ranbaxy/NPI label and will be marketed and actively promoted to doctors in hospitals as well as in clinics, jointly by the field forces of NC and NPI.

Ranbaxy CEO and MD Malvinder Mohan Singh said, ''It is our earnest intention to leverage the advantage of an early entry in the progressive opening up of the generic pharma market of Japan. We intend to rapidly introduce an array of generic therapies from our global portfolio.'' UNI SN GK AG1715